Literature DB >> 10221637

Drug interactions with psychostimulants.

J S Markowitz1, S D Morrison, C L DeVane.   

Abstract

The psychostimulants methylphenidate, dextroamphetamine, and pemoline are among the most common medications used in child and adolescent psychiatry. Often, these agents are used in combination with other medications. This review summarizes reported drug interactions and assesses both causality and clinical significance. A computerized search was undertaken using MEDLINE (1966 to 1998) to obtain all pertinent reports of adverse events associated with the coadministration of psychostimulants and other drugs. A total of 38 reports involving 25 different drugs from various classes were systematically evaluated along with research studies conducted to specifically assess drug interactions. Methylphenidate appeared to be involved primarily in pharmacokinetic interactions suggestive of cytochrome P450 inhibition while dextroamphetamine and pemoline were more often involved in apparent pharmacodynamic interactions. The published data support the safe use of psychostimulants with most classes of medications with few absolute contraindications.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10221637     DOI: 10.1097/00004850-199901000-00001

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  9 in total

Review 1.  Pharmacokinetics and clinical effectiveness of methylphenidate.

Authors:  H C Kimko; J T Cross; D R Abernethy
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

Review 2.  Assessing the roles of stimulants/stimulant-like drugs and dopamine-agonists in the treatment of bipolar depression.

Authors:  Bernardo Dell'Osso; Terence A Ketter; Laura Cremaschi; Gregorio Spagnolin; A Carlo Altamura
Journal:  Curr Psychiatry Rep       Date:  2013-08       Impact factor: 5.285

Review 3.  Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder.

Authors:  J S Markowitz; K S Patrick
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

4.  A longitudinal study of cytochrome P450 2D6 (CYP2D6) activity during adolescence.

Authors:  J Steven Leeder; Andrea Gaedigk; Krista J Wright; Vincent S Staggs; Sarah E Soden; Yvonne S Lin; Robin E Pearce
Journal:  Clin Transl Sci       Date:  2022-08-23       Impact factor: 4.438

5.  Patterns, Consequences, and Motives in Simultaneous Use of Prescription Stimulant Medication with Alcohol and Marijuana.

Authors:  Nicole Fossos-Wong; Jason R Kilmer; Alexander W Sokolovsky; Ha-Yoon Lee; Kristina M Jackson; Helene R White
Journal:  Subst Use Misuse       Date:  2021-09-09       Impact factor: 2.362

6.  An open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics.

Authors:  Paul Hammerness; Anna Georgiopoulos; Robert L Doyle; Linsey Utzinger; Mary Schillinger; Marykate Martelon; Kerry Brodziak; Joseph Biederman; Timothy E Wilens
Journal:  J Child Adolesc Psychopharmacol       Date:  2009-10       Impact factor: 2.576

Review 7.  Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices.

Authors:  Rafael de la Torre; Magí Farré; Mónica Navarro; Roberta Pacifici; Piergiorgio Zuccaro; Simona Pichini
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

8.  Combination pharmacotherapy for adult ADHD.

Authors:  Lenard A Adler; Lisa S Reingold; Melinda S Morrill; Timothy E Wilens
Journal:  Curr Psychiatry Rep       Date:  2006-10       Impact factor: 8.081

Review 9.  Methylphenidate for attention problems in epilepsy patients: Safety and efficacy.

Authors:  Beth A Leeman-Markowski; Jesse Adams; Samantha P Martin; Orrin Devinsky; Kimford J Meador
Journal:  Epilepsy Behav       Date:  2020-12-24       Impact factor: 2.937

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.